{"id":560362,"date":"2026-07-04T02:00:00","date_gmt":"2026-07-04T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/oral-glp-1-therapies-attain-1-and-oasis-4-the-next-leap-forward\/"},"modified":"2026-07-09T18:05:00","modified_gmt":"2026-07-09T16:05:00","slug":"oral-glp-1-therapies-attain-1-and-oasis-4-the-next-leap-forward","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/oral-glp-1-therapies-attain-1-and-oasis-4-the-next-leap-forward\/","title":{"rendered":"Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4\u2014The Next Leap Forward"},"content":{"rendered":"\n

Injectable GLP-1 receptor agonists and the dual GIP\/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless, real-world use remains limited\u2014due to the injection itself, costs, cold-chain requirements, supply shortages, and often unsatisfactory adherence to treatment. The World Health Organization clearly highlighted this disparity in 2025: Even with rapid expansion of production, fewer than 10% of those who could potentially be treated are expected to actually have access to these substances by 2030. An effective, easily scalable oral option <\/em>thus addresses not merely a matter of convenience, but a critical gap in care. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Injectable GLP-1 receptor agonists and the dual GIP\/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560363,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Obesity Treatment","footnotes":""},"category":[11548,11508,11384,11297,11388,11460,11503],"tags":[95232,19610,95231,39302,15545],"powerkit_post_featured":[],"class_list":["post-560362","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-endocrinology-and-diabetology","category-general-internal-medicine","category-nutrition","category-prevention-and-health-care","category-studies","tag-attain-1","tag-glp-1-en","tag-oasis-4","tag-peptide-en","tag-small-molecules-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-19 22:18:02","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":560840,"slug":"traitements-oraux-a-base-de-glp-1-attain-1-et-oasis-4-la-prochaine-avancee-majeure","post_title":"Traitements oraux \u00e0 base de GLP-1 : ATTAIN-1 et OASIS-4 \u2013 la prochaine avanc\u00e9e majeure","href":"https:\/\/medizinonline.com\/fr\/traitements-oraux-a-base-de-glp-1-attain-1-et-oasis-4-la-prochaine-avancee-majeure\/"},"it_IT":{"locale":"it_IT","id":560843,"slug":"terapie-orali-a-base-di-glp-1-attain-1-e-oasis-4-il-prossimo-passo-avanti","post_title":"Terapie orali a base di GLP-1: ATTAIN-1 e OASIS-4 \u2013 il prossimo passo avanti","href":"https:\/\/medizinonline.com\/it\/terapie-orali-a-base-di-glp-1-attain-1-e-oasis-4-il-prossimo-passo-avanti\/"},"pt_PT":{"locale":"pt_PT","id":560846,"slug":"terapias-orais-com-glp-1-attain-1-e-oasis-4-o-proximo-passo","post_title":"Terapias orais com GLP-1: ATTAIN-1 e OASIS-4 \u2013 o pr\u00f3ximo passo","href":"https:\/\/medizinonline.com\/pt-pt\/terapias-orais-com-glp-1-attain-1-e-oasis-4-o-proximo-passo\/"},"es_ES":{"locale":"es_ES","id":560849,"slug":"tratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso","post_title":"Tratamientos orales con GLP-1: ATTAIN-1 y OASIS-4: el siguiente paso","href":"https:\/\/medizinonline.com\/es\/tratamientos-orales-con-glp-1-attain-1-y-oasis-4-el-siguiente-paso\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=560362"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560362\/revisions"}],"predecessor-version":[{"id":560364,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560362\/revisions\/560364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/560363"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=560362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=560362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=560362"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=560362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}